1,538
Views
15
CrossRef citations to date
0
Altmetric
Reports

Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock

, , ORCID Icon, , , ORCID Icon, ORCID Icon, ORCID Icon, , , & show all
Pages 33-42 | Received 07 Jun 2017, Accepted 29 Sep 2017, Published online: 02 Jan 2018

References

  • World Health Organization. World Cancer Report 2014; pp. Chapter 1.1. ISBN 92-832-0429-8.
  • Lumachi F, Brunello A, Maruzzo M, Basso U, Basso SM. Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 2013;20(5):596–604. doi:10.2174/092986713804999303. PMID:23278394.
  • Steelman LS, Martelli AM, Cocco L, Libra M, Nicoletti F, Abrams SL, McCubrey JA. The therapeutic potential of mTOR inhibitors in breast cancer. Br J Clin Pharmacol. 2016;82(5):1189‐212. doi:10.1111/bcp.12958. PMID:27059645.
  • Hortobagyi GN. Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2. Neoplasia. 2015;17:279‐88. doi:10.1016/j.neo.2015.01.005. PMID:25810012.
  • Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25:2357‐62. doi:10.1093/annonc/mdu456. PMID:25231953.
  • Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, et al. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520‐29. doi:10.1056/NEJMoa1109653. PMID:22149876.
  • Xu K, Liu P, Wei W. mTOR signaling in tumorigenesis. Biochimica et Biophysica Acta. 2014;1846(2):638‐54. doi: 10.1016/j.bbcan.2014.10.007. PMID:25450580.
  • Laplante M, Sabatini DM. mTOR signaling at a glance J Cell Sci. 2009;122(Pt 20):3589‐94. doi: 10.1242/jcs.051011. PMID: 19812304.
  • Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926‐45. doi:10.1101/gad.1212704. PMID:15314020.
  • Khapre RV, Patel SA, Kondratova AA, Chaudhary A, Velingkaar N, Antoch MP, Kondratov RV. Metabolic clock generates nutrient anticipation rhythms in mTOR signaling. Aging (Albany NY). 2014;6(8):675‐89. doi:10.18632/aging.100686. PMID:25239872.
  • Khapre RV, Kondratova AA, Patel S, Dubrovsky Y, Wrobel M, Antoch MP, Kondratov RV BMAL1-dependent regulation of the mTOR signaling pathway delays aging. Aging (Albany NY). 2014;6(1):48‐57. doi:10.18632/aging.100633. PMID:24481314.
  • Cao R, Robinson B, Xu H, Gkogkas C, Khoutorsky A, Alain T, Yanagiya A, Nevarko T, Liu AC, Amir S, Sonenberg N. Translational control of entrainment and synchrony of the suprachiasmatic circadian clock by mTOR/4E-BP1 signaling. Neuron. 2013;79(4):712‐24. doi:10.1016/j.neuron.2013.06.026. PMID:23972597.
  • Cao R, Anderson FE, Jung YJ, Dziema H, Obrietan K. Circadian regulation of mammalian target of rapamycin signaling in the mouse suprachiasmatic nucleus. Neuroscience. 2011;181:79‐88. doi:10.1016/j.neuroscience.2011.03.005. PMID:21382453.
  • Okazaki H, Matsunaga N, Fujioka T, Okazaki F, Akagawa Y, Tsurudome Y, Ono M, Kuwano M, Koyanagi S, Ohdo S. Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma. Cancer Res. 2014;74(2):543‐51. doi:10.1158/0008-5472.CAN-12-3241. PMID:24253377.
  • Drägert K, Bhattacharya I, Hall MN, Humar R, Battegay E, Haas E Basal mTORC2 activity and expression of its components display diurnal variation in mouse perivascular adipose tissue. Biochem Biophys Res Commun. 2016:22;473(1):317‐22. doi:10.1016/j.bbrc.2016.03.102. PMID: 27016480.
  • Stephan FK, Zucker I. Circadian rhythms in drinking behavior and locomotor activity of rats are eliminated by hypothalamic lesions. Proc Natl Acad Sci U S A. 1972;69(6):1583‐6. doi:10.1073/pnas.69.6.1583. PMID:4556464.
  • Takahashi JS Transcriptional architecture of the mammalian circadian clock. Nat Rev Genet. 2017;18(3):164‐79. doi:10.1038/nrg.2016.150. PMID:27990019.
  • Fu L, Kettner NM. The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci. 2013;119:221‐82. doi:10.1016/B978-0-12-396971-2.00009-9. PMID:23899600.
  • Dallmann R, Okyar A, Lévi F. Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy. Trends Mol Med. 2016;22(5):430‐45. doi:10.1016/j.molmed.2016.03.004. PMID:27066876.
  • Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 2010;50:377‐421. doi:10.1146/annurev.pharmtox.48.113006.094626. PMID:20055686.
  • Giacchetti S, Li XM, OZTURK N, Cuvier C, Machowiak J, Arrondeau J, Chang-Marchand Y, Espié M, Okyar A, Lévi F Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancer (MBC) and in a mouse chronopharmacology investigation Abstract of San Antonio Breast Cancer Symposium 2016 Abstract N° 850329.
  • Rossetti S, Esposito J, Corlazzoli F, Gregorski A, Sacchi N. Entrainment of breast (cancer) epithelial cells detects distinct circadian oscillation patterns for clock and hormone receptor genes. Cell Cycle. 2012;11(2):350‐60. doi:10.4161/cc.11.2.18792. PMID:22193044.
  • Balsalobre A, Damiola F, Schibler U. A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell. 1998;93(6):929‐37. doi:10.1016/S0092-8674(00)81199-X. PMID:9635423.
  • Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156‐9. doi:10.1016/0003-2697(87)90021-2. PMID:2440339.
  • Ballesta A, Dulong S, Abbara C, Cohen B, Okyar A, Clairambault J, Lévi F. A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery. PLoS Comput Biol. 2011;7:e1002143. doi:10.1371/journal.pcbi.1002143. PMID:21931543.
  • Ramanathan C, Khan SK, Kathale ND, Xu H, Liu AC. Monitoring cell-autonomous circadian clock rhythms of gene expression using luciferase bioluminescence reporters. J Vis Exp. 2012;27(67):pii:4234. doi: 10.3791/4234. PMID: 23052244.
  • Leontieva OV, Blagosklonny MV Gerosuppression by pan-mTOR inhibitors Aging (Albany NY). 2016;30; 8(12):3535‐51. doi:10.18632/aging.101155. PMID:28077803.
  • Canaple L, Kakizawa T, Laudet V. The days and nights of cancer cells. Cancer Res. 2003;63(22):7545‐52. PMID:14633665.
  • Goldbeter A, Gérard C, Gonze D, Leloup J-C, Dupont G Systems biology of cellular rhythms, FEBS Lett. 2012;586(18):2955‐65. doi:10.1016/j.febslet.2012.07.041. PMID:22841722.
  • Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003;302:255‐9. doi:10.1126/science.1086271. PMID:12934012.
  • Gréchez-Cassiau A, Rayet B, Guillaumond F, Teboul M, Delaunay F The circadian clock component Bmal1 is a critical regulator of p21WAF1/CIP1 expression and hepatocyte proliferation. J Biol Chem. 2008;283:4535‐4542. doi:10.1074/jbc.M705576200. PMID:18086663.
  • Fu L, Pelicano H, Liu J, Huang P, Chi Lee C The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002;111: 41‐50. doi:10.1016/S0092-8674(02)00961-3. PMID:12372299.
  • Pérez-Roger I, Solomon DLC, Sewing A, Land H Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27Kip1 binding to newly formed complexes. Oncogene. 1997;14:2373‐81. doi:10.1038/sj.onc.1201197. PMID:9188852.
  • Feillet C, Krusche P, Tamanini F, Janssens RC, Downey MJ, Martin P, Teboul M, Saito S, Lévi F, Bretschneider T, et al. Phase locking and multiple oscillating attractors for the coupled mammalian clock and cell cycle. Proc Natl Acad Sci U S A. 2014;111(27):9828‐33. doi:10.1073/pnas.1320474111. PMID:24958884.
  • Cash E, Sephton SE, Chagpar AB, Spiegel D, Rebholz WN, Zimmaro LA, Tillie JM, Dhabhar FS Circadian disruption and biomarkers of tumor progression in breast cancer patients awaiting surgery. Brain Behav Immun. 2015;48:102‐14. doi:10.1016/j.bbi.2015.02.017. PMID:25728235.
  • Sephton SE, Sapolsky RM, Kraemer HC, Spiegel DJ Diurnal cortisol rhythm as a predictor of breast cancer survival. Natl Cancer Inst. 2000: 21;92(12):994‐1000. doi:10.1093/jnci/92.12.994. PMID:10861311.
  • Touitou Y, Lévi F, Bogdan A, Benavides M, Bailleul F, Misset JL Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors. J Cancer Res Clin Oncol. 1995;121(3):181‐8. doi:10.1007/BF01198101. PMID:7713990.
  • Blakeman V, Williams JL, Meng QJ, Streuli CH Circadian clocks and breast cancer. Breast Cancer Res. 2016;18(1):89. doi:10.1186/s13058-016-0743-z. PMID:27590298.
  • Reszka E, Przybek M Circadian Genes in Breast Cancer. Adv Clin Chem. 2016;75:53‐70. doi:10.1016/bs.acc.2016.03.005. PMID:27346616.
  • Cadenas C, van de Sandt L, Edlund K, Lohr M, Hellwig B, Marchan R, Schmidt M, Rahnenführer J, Oster H, Hengstler JG Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle. 2014;13(20):3282‐91. doi:10.4161/15384101.2014.954454. PMID:25485508.
  • Gutiérrez-Monreal MA, Treviño V, Moreno-Cuevas JE, Scott SP Identification of circadian-related gene expression profiles in entrained breast cancer cell lines. Chronobiol Int. 2016;33(4):392‐405. doi:10.3109/07420528.2016.1152976. PMID:27010605.
  • Xiang S, Mao L, Duplessis T, Yuan L, Dauchy R, Dauchy E, Blask DE, Frasch T, Hill SM Oscillation of clock and clock controlled genes induced by serum shock in human breast epithelial and breast cancer cells: regulation by melatonin. Breast Cancer (Auckl). 2012;6:137‐50. doi: 10.4137/BCBCR.S9673. PMID:23012497.
  • Koziczak M, Hynes NE Cooperation between fibroblast growth factor receptor-4 and ERBB2 in regulation of cyclin D1 translation. J Biol Chem. 2004;279(48):50004‐11. doi:10.1074/jbc.M404252200. PMID:15377668.
  • Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature. 2005;433:477‐80. doi:10.1038/nature03205. PMID:15690031.
  • Leontieva OV, Lenzo F, Demidenko ZN, Blagosklonny MV Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells, Cell Cycle. 2012: 11:24:4642‐9; doi:10.4161/cc.22937.
  • Edgar RS, Green EW, Zhao Y, van Ooijen G, Olmedo M, Qin X, Xu Y, Pan M, Valekunja UK, Feeney KA, et al. Peroxiredoxins are conserved markers of circadian rhythms. Nature. 2012;485(7399):459‐64. doi: 10.1038/nature11088. PMID:22622569.
  • Zhu B, Zhang Q, Pan Y, Mace EM, York B, Antoulas AC, Dacso CC, O'Malley BW. A Cell-Autonomous Mammalian 12 hr Clock Coordinates Metabolic and Stress Rhythms, Cell Metab. 2017;25(6):1305‐19. e9. doi: 10.1016/j.cmet.2017.05.004.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.